SSRIs
|
Low risk. Risk-benefit analysis. Reported increased incidence of
cardio-septal defects.
|
No statistical difference on outcomes yet data is limited.
Further research required.
|
Amber
|
PPIs |
Current data suggests omeprazole is safe however limited
data on other PPI’s. |
Negative impact on sperm if taken
>6m prior to ART. Further research required to assess
maternal effects. |
Amber |
Metformin |
Considered safe; insufficient data on
1st trimester and miscarriage risk. |
Beneficial in
PCOS patients undergoing ART. Further research required for others. |
Amber |
Levothyroxine |
Considered safe. |
Positive effect on live
birth rates in subclinical hypothyroidism. Further research required on
paternal effects. |
Green |
Anti-hypertensives
|
ACEi/ARBs: proven fetal renal risk in 2nd and
3rd trimesters. CCBs: animal studies demonstrate risk
but lack of data in humans. Beta-blockers: labetalol considered
safe.
|
Further research required for maternal effects. Beta-blockers: no
adverse effects on sperm quality.
ACEi/ARBs, CCBs: isolated impacts on sperm
Diuretics: no impact
|
Amber ¥
|
Asthma medications
|
Increased risk of cleft palate, renal dysplasia and gastroschisis with
inhaled beta2 agonists. Inhaled corticosteroids have not been associated
with adverse impacts. However, uncontrolled asthma can cause significant
impacts
|
Further research required.
|
Amber (inhaled beta2 agonists)
Green (inhaled corticosteroids)
|
Steroids |
Further research required. Limited association with
low birth weight and cleft lip/palate |
Further research required. |
Amber |